Oxford Immunotec Global 10-K 1 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 21, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	Oxford Immunotec Global PLC
Entity Central Index Key	1,586,049
Trading Symbol	oxfd
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		22,712,311
Entity Public Float			$ 196,841,358
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 59,110	$ 83,715
Accounts receivable, net	13,265	7,058
Inventory, net	7,437	7,099
Prepaid expenses and other	2,390	3,592
Total current assets	82,202	101,464
Restricted cash, non-current	200	80
Property and equipment, net	7,793	6,284
In-process research and development	16,170	1,782
Goodwill	3,822	45
Other intangible assets, net	11,017	179
Other assets	2,808	18
Total assets	124,012	109,852
Current liabilities:
Accounts payable	3,201	3,799
Accrued liabilities	14,282	9,949
Contingent purchase price consideration	882
Deferred income	41	1,654
Current portion of loans payable	84	79
Total current liabilities	18,490	15,481
Long-term portion of loans payable	29,601	386
Contingent purchase price consideration	2,593	1,293
Other liabilities	364
Total liabilities	51,048	17,160
Commitments and contingencies (Note 15)
Shareholders' equity:
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at December 31, 2016 and 2015, 22,635,431 and 22,549,488 shares issued and outstanding at December 31, 2016 and 2015, respectively	243	243
Additional paid-in capital	249,128	244,033
Accumulated deficit	(168,656)	(146,307)
Accumulated other comprehensive loss	(7,751)	(5,277)
Total shareholders’ equity	72,964	92,692
Total liabilities and shareholders’ equity	$ 124,012	$ 109,852

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - £ / shares	Dec. 31, 2016	Dec. 31, 2015	Jan. 29, 2015
Common stock, nominal value (in GBP per share)	£ 0.006705	£ 0.006705	£ 0.006705
Common stock, shares authorized (in shares)	36,183,293	36,183,293
Common stock, shares issued (in shares)	22,635,431	22,549,488
Common stock, shares outstanding (in shares)	22,635,431	22,549,488

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue
Product	$ 36,430	$ 30,207	$ 25,407
Service	49,648	32,575	24,098
Total revenue	86,078	62,782	49,505
Cost of revenue
Product	13,956	13,297	11,225
Service	25,516	16,247	12,784
Total cost of revenue	39,472	29,544	24,009
Gross profit	46,606	33,238	25,496
Operating expenses:
Research and development	13,881	10,381	6,961
Sales and marketing	34,964	30,402	25,487
General and administrative	23,181	16,010	14,837
Change in fair value of contingent purchase price consideration	(1,208)	202	72
Intangible assets impairment charges	1,765	419
Total operating expenses	72,583	57,414	47,357
Loss from operations	(25,977)	(24,176)	(21,861)
Other income (expense):
Interest expense, net	(864)	(67)	(52)
Foreign exchange gains (losses)	1,364	(143)	(352)
Other (expense) income	(646)	54	245
Loss before income taxes	(26,123)	(24,332)	(22,020)
Income tax benefit (expense)	3,774	(146)	(154)
Net loss	$ (22,349)	$ (24,478)	$ (22,174)
Net loss per ordinary share—basic and diluted (in dollars per share)	$ (1)	$ (1.12)	$ (1.28)
Weighted-average shares used to compute net loss per ordinary share—basic and diluted (in shares)	22,353,713	21,781,933	17,310,148

Consolidated Statements of Othe

Consolidated Statements of Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ (22,349)	$ (24,478)	$ (22,174)
Other comprehensive loss, net of taxes:
Foreign currency translation adjustment, net of taxes	(2,474)	(707)	(822)
Other comprehensive loss, net of taxes	(2,474)	(707)	(822)
Total comprehensive loss	$ (24,823)	$ (25,185)	$ (22,996)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2013	$ 188	$ 183,967	$ (99,655)	$ (3,748)	$ 80,752
Exercise of share options	1	13			14
Issuance of shares from option plan	3	(3)
Issuance of shares from exercise of warrants		318			318
Share-based compensation expense		2,521			2,521
Other comprehensive loss				(822)	(822)
Net loss			(22,174)		(22,174)
Balance at Dec. 31, 2014	192	186,816	(121,829)	(4,570)	60,609
Exercise of share options	1	19			20
Share-based compensation expense		3,485			3,485
Other comprehensive loss				(707)	(707)
Net loss			(24,478)		(24,478)
Balance at Dec. 31, 2015	243	244,033	(146,307)	(5,277)	92,692
Issuance of shares in secondary offering	50	53,713			53,763
Exercise of share options		76			76
Share-based compensation expense		5,019			5,019
Other comprehensive loss				(2,474)	(2,474)
Net loss			(22,349)		(22,349)
Balance at Dec. 31, 2016	$ 243	$ 249,128	$ (168,656)	$ (7,751)	$ 72,964

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (22,349,000)	$ (24,478,000)	$ (22,174,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of intangible assets and loan fees	3,094,000	2,142,000	1,742,000
Change in fair value of contingent purchase price consideration	244,000	202,000	72,000
Write-off of contingent purchase price consideration	(1,452,000)
Intangible assets impairment charges	1,765,000	419,000
Share-based compensation expense	5,019,000	3,485,000	2,521,000
Loss on change in fair value of warrants			22,000
Loss on disposal of property and equipment		33,000
Changes in operating assets and liabilities:
Accounts receivable, net	(6,515,000)	(416,000)	(2,311,000)
Inventory, net	(741,000)	(893,000)	(1,214,000)
Prepaid expenses and other assets	(2,926,000)	(898,000)	(594,000)
Accounts payable	(1,145,000)	1,363,000	(109,000)
Accrued liabilities	4,753,000	2,742,000	696,000
Deferred income	(1,668,000)	(250,000)	572,000
Net cash used in operating activities	(21,921,000)	(16,549,000)	(20,777,000)
Cash flows from investing activities
Purchases of property and equipment	(2,383,000)	(3,425,000)	(3,014,000)
Purchases of intangible assets		(43,000)	(354,000)
Cash paid for acquisitions, net of cash acquired	(27,515,000)		(1,716,000)
Proceeds on sales of property and equipment		34,000
Change in restricted cash	(120,000)	312,000	57,000
Net cash used in investing activities	(30,018,000)	(3,122,000)	(5,027,000)
Cash flows from financing activities
Proceeds from issuance of ordinary shares		53,763,000
Proceeds from exercise of share options	76,000	20,000	14,000
Proceeds from term loan, net	29,457,000
Discount on the line of credit	(50,000)
Debt issuance costs	(289,000)
Payments on loan	(80,000)	(122,000)	(165,000)
Net cash provided by (used in) financing activities	29,114,000	53,661,000	(151,000)
Effect of exchange rate changes on cash and cash equivalents	(1,780,000)	(440,000)	(374,000)
Net (decrease) increase in cash and cash equivalents, excluding restricted cash	(24,605,000)	33,550,000	(26,329,000)
Cash and cash equivalents at beginning of year	83,715,000	50,165,000	76,494,000
Cash and cash equivalents at end of year	59,110,000	83,715,000	50,165,000
Supplemental disclosures
Cash paid for interest	450,000	41,000	50,000
Cash paid for taxes	141,000	50,000	115,000
Noncash investing and financing activities
Warrants liability reclassified to additional paid-in capital upon exercise of warrants			$ 318,000

Note 1 - Description of Busines

Note 1 - Description of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Description of business Oxford Immunotec Global PLC, or the Company, is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for under-served immune-regulated conditions. The Company’s current product lines and development activities principally focus on four tend On July 1, 2016, On October 12, 2016, $6 $6 three Basis of presentation, accounting principles and principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, and include the financial statements of Oxford Immunotec Global PLC, a company incorporated in England and Wales and its wholly-owned subsidiaries, collectively referred to as the Company. All intercompany accounts and transactions have been eliminated upon consolidation. Segment reporting The Company operates in one Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and that affect the reported amounts of revenue and expenditures during the reporting periods. Actual results could differ from those estimates and assumptions used. Foreign currency translation The functional currency for Oxford Immunotec Global PLC is the U.S. Dollar. The functional currency for the Company’s operating subsidiaries are the Pound Sterling for Oxford Immunotec Limited, the U.S. Dollar for Oxford Immunotec Inc. and Immunetics, Inc., the Yen for Oxford Immunotec K.K., the Yuan for Oxford Immunotec (Shanghai) Medical Device Co. Ltd., the Euro for Boulder Diagnostics Europe GmbH and the Hong Kong Dollar for Oxford Immunotec Asia Limited. Revenue and expenses of foreign operations are translated into U.S. Dollars at the average rates of exchange during the year. Assets and liabilities of foreign operations are translated into U.S. Dollars at year-end rates. The Company reflects resulting translation gains or losses in accumulated other comprehensive income, which is a component of shareholders’ equity. The Company does not record tax provisions or benefits for the net changes in foreign currency translation adjustments, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries. Realized and unrealized foreign currency transaction gains or losses, arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies, are included in “Other income (expense)” in the consolidated statements of operations. Concentration of risks In the year ended December 31, 2016, two 10% March 15% 14% Cash and cash equivalents and restricted cash The Company considers all highly liquid investments purchased with maturities at acquisition of three The Company maintains its available cash balances in cash, money market funds primarily invested in U.S. government securities, and bank savings accounts in the United States, United Kingdom, Germany, Japan and Hong Kong. The Company maintains deposits in government insured financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Restricted cash relates to collateral for procurement cards issued by a U.S. commercial bank. Accounts receivable Accounts receivable are primarily amounts due from customers including hospitals, public health departments, commercial testing laboratories, distributors and universities in addition to third Accounts receivable are reported net of an allowance for uncollectible accounts. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management’s analysis of current and past due accounts, collection experience and other relevant information. The Company’s provision for uncollectible accounts is recorded as a bad debt expense and included in general and administrative expenses. Account balances are written-off against the allowance when it is probable that the receivable will not be recovered. Although the Company believes amounts provided are adequate, the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided. Inventory Inventory consists of finished goods and raw materials. The Company does not maintain work in progress balances as the nature of the manufacturing process does not allow for test kits to be left in a partially manufactured state. Inventory is removed at cost. Inventory is stated at the lower of cost or market. Cost is determined by the actual cost of components by batch plus estimated labor and overhead costs per unit. Market value is based on an estimated selling price less any costs expected to be incurred to completion and sale. The Company reviews the components of its inventory on a periodic basis for excess, obsolete or impaired inventory, and records a reserve for the identified items. Property and equipment Property and equipment are stated at cost. Property and equipment includes specialized shipping containers provided to customers, in the United States, for transporting samples to the Company’s laboratory for testing. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three ten three Revenue recognition The Company derives product revenue from the sale of its diagnostic test kits and related accessories to a broad range of customers including hospitals, public health departments, commercial testing laboratories, importers and distributors. Product revenue is generally paid directly by the customer and is recognized on an accrual basis when the following revenue recognition criteria are met: (1) (2) (3) (4) No product return rights are extended to customers of the Company. The Company derives service revenue from tests performed on samples sent by customers to its diagnostic laboratories in the United States and the United Kingdom, and to contracted laboratories in other countries. Service revenue in the United Kingdom and revenue from direct bill customers in the United States are recognized on an accrual basis when the following revenue recognition criteria are met: (1) (2) (3) (4) In the United States, the Company also generates revenue from payments that are received from a variety of third third Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations. Cost of revenue: cost of product and cost of service Cost of product revenue consists primarily of costs incurred in the production process, including costs of raw materials and components, assembly labor and overhead, quality management, royalties paid under licensing agreements, the U.S. medical device excise tax and packaging and delivery costs. Cost of service revenue consists primarily of costs incurred in the operation of the Company’s diagnostic laboratories including labor and overhead, kit costs, quality management, consumables used in the testing process and packaging and delivery costs. Shipping and handling The Company does not normally bill its service customers for shipping and handling charges. Charges relating to inbound and outbound freight costs are incurred by the Company and recorded within cost of service. The Company generally bills product customers for shipping and handling and records the customer payments as product revenue. The associated costs are recorded as cost of product sold. Impairment of long-lived assets The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may may Business combinations For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods. When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third third Goodwill and indefinite-lived intangible assets Goodwill Goodwill is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate that all, or a portion, of the carrying value of the reporting unit may two first 50%) first may Indefinite-lived intangible assets The Company’s indefinite-lived intangible assets consist of acquired in-process research and development, or IPR&D, related to the Company’s business combinations with Boulder, Imugen and Immunetics, which were recorded at fair value on the acquisition dates. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may first 50%) first may The determinations as to whether, and, if so, the extent to which, acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends. Definite-lived intangible assets Intangible assets include technology licenses which are capitalized and amortized over estimated useful lives (generally in the range of five twenty Derivative financial instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, interest rate or foreign currency risks. The Company reviews the terms of the shares it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as other income or expense. When equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first Fair value of financial instruments The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of December 31, 2016 2015, 2 Research and development expenses Research and development expenses include all costs associated with the development of the Company’s T-SPOT technology platform and potential future products including new diagnostic tests that utilize the T-SPOT technology platform and are charged to expense as incurred. In addition, with the acquisition of Boulder in 2014 2016, Share-based compensation The Company accounts for share-based compensation arrangements with employees, officers and directors by recognizing compensation expense based on the grant date fair value of share-based transactions in the consolidated financial statements. Share-based compensation for options is based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for share options and recognized as expense on a straight-line basis over the requisite service period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility, expected term and forfeiture rates. The expected volatility rates are estimated based on the actual volatility of comparable public companies over a historical period equal in length to the expected term. The expected terms represent the average time that options are expected to be outstanding based on the midpoint between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses an expected dividend yield of zero Certain employees have been granted restricted share units, or RSUs, and restricted shares. The fair value of RSUs and restricted shares are calculated based on the closing sale price of the Company’s ordinary shares on the date of grant. The cumulative expense recognized for share-based transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit for a period represents the movement in cumulative expense recognized as of the beginning and end of that period. No expense is recognized for awards that do not ultimately vest. Where the terms of an equity award are modified, the minimum expense recognized is the expense as if the terms had not been modified if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based compensation, or is otherwise beneficial to the employee as measured at the date of modification. Where a share-based compensation award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph. Upon exercise, share options are redeemed for newly issued ordinary shares. Income taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and its financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company adheres to the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken, or expected to be taken, in a tax return. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% not December 31, 2016 2015. Basic and diluted net loss per ordinary share Basic and diluted net loss per ordinary share is determined by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. As the Company reports net losses, outstanding share options, RSUs and restricted shares have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per ordinary share for each period are the same. Recent accounting pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09, 2014 09, 2014 09 December 15, 2017. December 15, 2016. 2014 09 first 2018 2014 09 may In August 2014, 2014 15, Presentation of Financial Statements - Going Concern 2014 15. 2014 15 December 15, 2016 2014 15 one 2014 15 October 1, 2016 on its financial position, results of operations or related disclosures. In July 2015, 2015 11, Simplifying the Measurement of Inventory 2015 11. 2015 11 2015 11 December 15, 2016. 2015 11 2015 11 In February 2016, 2016 02, Leases 2016 02. 2016 02 December 15, 2018. 2016 02 may In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09. 2016 09 December 15, 2016. 2016 09 In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. 2016 13 may In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments 2016 15. 2016 15 December 15, 2017. 2016 15 may In October 2016, 2016 16, Income Taxes 2016 16. December 15, 2017, 2016 16 2016 16 In November 2016, 2016 18, Restricted Cash 2016 18. 2016 18 December 15, 2017, 2016 18 In January 2017, 2017 01, Business Combinations 2017 01. 2017 01 December 15, 2017, 2017 01 In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. 2017 04 may Under the U.S. Jumpstart our Business Startups Act, or the JOBS Act, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. The Company irrevocably elected not to avail itself of this exemption from new or revised accounting standards and, therefore, it is subject to the same new or revised accounting standards as public companies that are not emerging growth companies.

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three Level I—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level II—Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level III—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The following tables present information about the balances of liabilities measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 2 3 not Fair v alue m easurements at December 31, 201 6 u sing (in thousands) December 31, 6 Quoted p rices in a ctive m arkets for i dentical a ssets Significant o ther observable nputs Significant u nobservable i nputs Liabilities: Contingent purchase price consideration $ 3,475 $ — $ — $ 3,475 Total $ 3,475 $ — $ — $ 3,475 Fair v alue m easurements at December 31, 201 5 u sing (in thousands) December 31, 5 Quoted p rices in a ctive m arkets for i dentical a ssets Significant o ther observable nputs Significant u nobservable i nputs Liabilities: Contingent purchase price consideration $ 1,293 $ — $ — $ 1,293 Total $ 1,293 $ — $ — $ 1,293 The following tables provide a summary of changes in the fair value of the Company's Level 3 December 31: (in thousands) 201 6 Balance – beginning $ 1,293 Immunetics acquisition (Note 17) 3,444 Change in fair value of contingent purchase price consideration 244 Write-off of Boulder contingent purchase price consideration (1,452 ) Foreign currency adjustment (54 ) Balance – ending $ 3,475 (in thousands) 2015 Balance – beginning $ 1,218 Change in fair value of c ontingent purchase price consideration 202 Foreign currency adjustment (127 ) Balance – ending $ 1,293 During the fourth 2016, $901,000. $551,000. On October 12, 2016, $6.0 three . The fair value of these milestone payments has been estimated to be $3.4 4.4%, 3 The Company has a term loan outstanding under the MidCap agreement. The amount outstanding on its 2016 December 31, 2016, 2

Note 3 - Accounts Receivable, N

Note 3 - Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Financing Receivables [Text Block]	3. , net Accounts receivable, net, consisted of the following as of: December 31, (in thousands) 201 6 201 5 Accounts receivable $ 14,050 $ 7,372 Less allowance for uncollectible accounts receivable (785 ) (314 ) Accounts receivable, net $ 13,265 $ 7,058 Activity for the allowance for uncollectible accounts receivable is as follows: December 31, (in thousands) 201 6 201 5 201 4 Balance at beginning of period $ (314 ) $ (114 ) $ (165 ) Provision for bad debt expense (471 ) (200 ) — Write-off, net of recoveries — — 51 Balance at end of period $ (785 ) $ (314 ) $ (114 )

Note 4 - Inventory, Net

Note 4 - Inventory, Net	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. , net Inventory consisted of the following as of: December 31, (in thousands) 201 6 201 5 Raw materials $ 4,928 $ 3,925 Finished goods 2,509 3,174 Inventory $ 7,437 $ 7,099

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment, net consists of the following as of: December 31, (in thousands) 201 6 201 5 Laboratory equipment $ 5,971 $ 4,865 Leasehold improvements 3,199 2,783 Office equipment, furniture and fixtures 3,364 2,841 Software 1,479 1,172 Specialized shipping containers 2,655 2,177 Construction in progress 848 200 Property and equipment 17,516 14,038 Less accumulated depreciation (9,723 ) (7,754 ) Property and equipment, net $ 7,793 $ 6,284 For the years ended December 31, 2016, 2015 2014, $2.6 $2.0 $1.7 Depreciable lives range from three ten three For the years ended December 31, 2016 2015,

Note 6 - Intangible Assets

Note 6 - Intangible Assets	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. i ntangible assets The following table sets forth the changes in the carrying amount of goodwill for the years ended December 31, 2015 2016 Balance at December 31, 2014 $ 50 Foreign currency adjustment (5 ) Balance at December 31, 2015 45 Imugen acquisition (Note 17) 2,645 Immunetics acquisition (Note 17) 1,177 Impairment charge – Boulder goodwill (43 ) Foreign currency adjustment (2 ) Balance at December 31, 2016 $ 3,822 Acquired intangible assets consisted of the following as of December 31, 2016 2015 As of December 31 , 2016 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Imugen in-process research and development Indefinite $ 9,200 $ — $ 9,200 Imugen technology - clinical 15 5,100 170 4,930 Imugen customer relationships 10 2,700 135 2,565 Imugen trademarks / trade names 16 1,900 59 1,841 Immunetics in-process research and development Indefinite 6,970 — 6,970 Immunetics technology – clinical 15 860 9 851 Immunetics customer relationships 5 - 11 400 11 389 Immunetics trade name 5 290 9 281 Immunetics grants 2 50 4 46 Other 5 - 10 632 518 114 Total $ 28,102 $ 915 $ 27,187 As of December 31, 2015 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Boulder in-process research and development Indefinite $ 1,782 $ — $ 1,782 Other 5 - 10 758 579 179 Total $ 2,540 $ 579 $ 1,961 The weighted average amortization period of our finite-lived intangible assets is 13 December 31, 2016, 2015 2014 $435,000, $92,000 $43,000, Amortization expense related to acquired intangible assets is estimated at $1.0 2017 2018 $0.9 2019 2021. The acquired IPR&D assets include $9.2 $7.0 fourth 2016, $1.4 IPR&D acquired in a business combination is capitalized at fair value and is subject to impairment testing at least annually until the underlying project is completed. Once the project is completed, the carrying value of IPR&D is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the acquired IPR&D are expensed as incurred. For more information on the acquisitions, see Note 17

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued liabilities consist of the following as of: December 31, (in thousands) 201 6 201 5 Employee related expenses $ 6,592 $ 4,478 Royalties 4,423 3,498 Clinical trials 1,135 442 Professional services 387 333 Sales and use taxes payable 155 193 Other accrued liabilities 1,590 1,005 Total accrued liabilities $ 14,282 $ 9,949

Note 8 - Loans Payable

Note 8 - Loans Payable	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	8 . Loans payable In June 2013, 14,500 $582,000 80% 840, Leases December 31, 2016, $71,000 $236,000 On October 4, 2016, $40 $30 five 7.60% first 24 48 $10 five 4.45%. 0.50% may $10 $60 If the credit facility is terminated prior to the end of the term, the Company will pay to the lenders a fee as compensation for the costs of being prepared to make funds available to the Company throughout the term equal to an amount determined by multiplying the revolving line of credit commitment amount by 3.0% first 2.0% second 1.0% third Upon repayment in full of the loan, the Company is obligated to make a final payment fee equal to 6% The credit facility is collateralized by a perfected first Under the Credit Agreement, the Company is subject to affirmative covenants which are customary for financings of this type, including, but not limited to, the obligations of the Company to: (i) deliver financial statements and other reports to MidCap, (ii) maintain insurance, (iii) maintain good standing, (iv) comply with all laws and material contracts, (v) provide certain other information and notices to MidCap, and (vi) protect the Company’s intellectual property. The Company is also subject to negative covenants customary for financings of this type, including, but not limited to, that without the prior consent of MidCap, the Company may The Company is also subject to financial covenants customary to financings of this type, which require the Company to achieve quarterly targets based on trailing 12 December 31, 2016, The MidCap Agreement provides that events of default include: (i) failure to make payment of principal or interest when required, (ii) failure to perform obligations under the MidCap agreement and related documents, (iii) defaults in other indebtedness and breaches of material agreements of the Company, (iv) voluntary case or other proceeding by the Company seeking liquidation, reorganization or other relief, (v) if the Company ceases to be a publicly-listed and reporting company and (vi) certain other events, including certain adverse actions taken by the FDA, CMS or other governmental authorities. Upon an event of default, the Company’s obligations under the MidCap agreement may, The balance of the secured term loan due to MidCap as of December 31, 2016 $30 Future minimum payments required under the term loan and the revolving line of credit as of December 31, 2016 (in thousands) Term Loan 2017 $ — 2018 1,667 2019 10,000 2020 10,000 2021 8,333 Thereafter — Total minimum payments $ 30,000 In addition to the MidCap term loan payments listed above, the Company is required to pay an exit fee of 6.0% $1.8 he 6% $1.8 The Company did not borrow under the revolving line of credit during 2016.

Note 9 - Share Capital

Note 9 - Share Capital	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Share capital On January 29, 2015, 4,255,319 £0.006705, $11.75 $11.045 30 638,297 January 30, 2015, $57.5 $53.8 February 4, 2015. During 2016, 85,943 December 31, 2016, 36,183,293 22,635,431

Note 10 - Share Option and Equi

Note 10 - Share Option and Equity Incentive Plan	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	1 0 . Share option and equity incentive plans The Company has issued share options since 2003, 2014 2015 two 2008 2013 2013 2008 In November 2013, 2013 2013 2013 2,684,563 January 1 st January 1, 2023 4% December 31 st may At December 31, 2016, 2,004,074 2013 Under both the 2008 2013 2013 ten four 2015, 0% second first 2008 second first second 2013 2015, four 40% second 30% third 30% fourth The fair value of the options was estimated at the grant date using the Black-Scholes option pricing model, taking into account the terms and conditions upon which options are granted. The fair value of the options is amortized on a straight-line basis over the requisite service period of the awards. The weighted-average grant date fair value per share relating to share options granted under the Plans during the years ended December 31, 2016, 2015 2014 $4.53, $6.33 $9.32, The fair value of each option granted under the Plans has been calculated on the date of grant using the following assumptions: 201 6 201 5 201 4 Expected dividend yield (%) — — — Expected volatility (%) 43.70 44.11 46.87 Risk-free interest rate (%) 1.53 1.66 1.86 Expected life of option (years) 6.16 6.19 6.19 Weighted-average share price ($) 10.29 14.15 19.66 Weighted-average exercise price ($) 10.29 14.15 19.66 Model used Black-Scholes Model Black-Scholes Model Black-Scholes Model Expected dividend yield: no Expected volatility: November 2013, Risk-free interest rate: Expected life of options (in years): November 2013, Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company estimates forfeitures based on historical termination behavior. For the years ended December 31, 2016, 2015 2014, 5% The following table illustrates the number of ordinary shares and weighted-average exercise prices, or WAEP, of, and movements in, share options during the year: Number of ordinary shares WAEP Outstanding as of January 1, 2016 2,425,426 $ 9.03 Granted 749,964 10.29 Exercised (85,943 ) 0.82 Forfeited (239,667 ) 14.27 Outstanding as of December 31, 2016 2,849,780 9.15 Vested or expected to vest as of December 31, 2016 2,790,851 $ 9.08 Exercisable as of December 31, 2016 1,671,179 $ 6.81 The following table illustrates the number of restricted shares and RSUs, and weighted-average fair value, or WAFV, of, and movements in, restricted shares and RSUs during the year: Number of ordinary shares WAFV Unvested balance as of January 1, 2016 366,739 $ 19.72 Granted 108,361 10.21 Cancelled (57,530 ) 16.17 Vested (88,105 ) 22.99 Unvested balance as of December 31, 2016 329,465 16.34 As of December 31, 2016, $5.0 $3.3 2.4 1.9 The aggregate intrinsic value of all share options outstanding under the Plans as of December 31, 2016 2015 $19.2 $12.6 December 31, 2016 $15.6 During the years ended December 31, 2016, 2015 2014, 85,943, 41,222 65,054 $76,000 2016, $20,000 2015 $14,000 2014. December 31, 2016, 2015 2014 $1.0 $0.5 $0.9 A summary of the activity of the Company’s unvested share options is as follows: Number of shares Weighted- average grant date fair value Balance as of December 31, 2015 1,124,443 $ 6.53 Granted 749,964 4.53 Vested (479,295 ) 5.92 Forfeited (216,510 ) 6.08 Balance as of December 31, 2016 1,178,602 5.61 The total fair value of shares vested for the years ended December 31, 2016, 2015 2014 $2.9 $1.9 $1.0 The impact on the Company’s results of operations from share-based compensation for the years ended December 31, 2016 , 2015 and 2014 , was as follows: (in thousands) 2016 2015 201 4 Cost of revenue $ 57 $ 529 $ 330 Research and development 548 86 87 Sales and marketing 1,725 1,045 949 General and administrative 2,689 1,825 1,155 Total share-based compensation $ 5,019 $ 3,485 $ 2,521 For the year ended December 31, 2016, $3.2 $1.8 December 31, 2015, $2.4 $1.1 December 31, 2014, $1.6 $0.9

Note 11 - Net Loss Per Ordinary

Note 11 - Net Loss Per Ordinary Share	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	1 1 . Net loss per ordinary share The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share: Year ended December 31, ( $ i n thousands ) 201 6 201 5 201 4 Numerator: Net loss per ordinary share $ (22,349 ) $ (24,478 ) $ (22,174 ) Denominator: Weighted-average ordinary shares outstanding-basic 22,353,713 21,781,933 17,310,148 Dilutive effect of ordinary share equivalents resulting from ordinary share options, ordinary share warrants and preferred ordinary shares (as converted) — — — Weighted-average ordinary shares outstanding-diluted 22,353,713 21,781,933 17,310,148 The following numbers of outstanding ordinary share options, restricted shares and RSUs were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Year ended December 31, 201 6 201 5 201 4 Options to purchase ordinary shares 1,065,655 1,108,240 1,194,612 Unvested restricted shares and RSUs 329,465 366,739 275,500

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. The components of loss before income taxes are as follows for the years ended December 31: (in thousands) 201 6 201 5 201 4 Domestic (United Kingdom) $ (730 ) $ 1,400 $ (158 ) Foreign (United States) (25,393 ) (25,732 ) (21,862 ) Loss before income taxes $ (26,123 ) $ (24,332 ) $ (22,020 ) The components for the income tax benefit (expense) are as follows for the years ended December 31: (in thousands) 201 6 201 5 20 14 Current: Federal $ — $ — $ — U.K. — — — Japan (85 ) (116 ) (119 ) China (12 ) — — State (51 ) (30 ) (35 ) Total current provision (148 ) (146 ) (154 ) Deferred: Federal 752 — — U.K. 2,630 — — State 540 — — Total deferred benefit 3,922 — — Income tax benefit (expense) 3,774 (146 ) (154 ) Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s effective income tax rate differs from the statutory domestic (United Kingdom) income tax rate as follows for the years ended December 31: 201 6 201 5 201 4 Income tax rate 20.0 % 20.3 % 21.5 % U.K. research and development credit 1.8 1.3 1.7 Other (2.1 ) (1.1 ) (1.2 ) Effect of foreign tax rate differential 16.8 10.7 17.9 Valuation allowance (22.1 ) (31.7 ) (40.6 ) Effective income tax rate 14.4 % (0.5 )% (0.7 )% The Company is headquartered in the United Kingdom and the effective U.K. corporate tax rate for the years ended December 31, 2016, 2015, 2014 20.0%, 20.3%, 21.5%, 34% December 31, 2016, 2015 2014. 2013 through 2016 . With a few exceptions, the Company is no longer subject to examinations by tax authorities for the tax years 2012 and prior. However, net operating losses from the tax years 2012 and prior would be subject to examination if and when used in a future tax return to offset taxable income. The Company’s policy is to recognize income tax related penalties and interest, if any, in its provision for income taxes and, to the extent applicable, in the corresponding income tax assets and liabilities, including any amounts for uncertain tax positions. The United Kingdom’s Summer Finance Bill, which was enacted on September 15, 2016, 19% April 1, 2017 17% April 1, 2020. 17% Significant components of the Company’s deferred tax assets and deferred tax liabilities are as follows for the years ended December 31: (in thousands) 201 6 201 5 Deferred tax assets: Long term deferred tax assets: U.S. federal net operating losses $ 42,165 $ 32,095 State net operating loss (net of federal) 5,198 4,021 U.S. federal research and development credit 273 155 U.K. net operating loss 2,419 5,217 Share options 1,884 1,251 Accrued liabilities 526 177 State credits 85 — Other — 160 Total deferred tax assets 52,550 43,076 Valuation allowance (46,473 ) (43,076 ) Total deferred tax assets $ 6,077 $ — Deferred tax liabilities: Long term deferred tax liabilities: Other assets $ (29 ) $ — Intangible assets (3,418 ) — Total deferred tax liabilities $ (3,447 ) $ — For the years ended December 31, 2016 2015, $14.2 $29.0 December 31, 2016 2015 $125.3 $95.5 December 31, 2016 2015 $112.5 $85.8 The U.S. federal and state net operating loss carryforwards begin to expire in 2027 2016, For the year ended December 31, 2016, $2.6 The following table reflects the rollforward of the Company’s valuation allowance: (in thousands) 201 6 201 5 201 4 Beginning of year (January 1) $ 43,076 $ 35,361 $ 26,413 Increase in valuation allowance 3,397 7,715 8,948 End of year (December 31) $ 46,473 $ 43,076 $ 35,361 The Company reviewed its historical tax filings and tax positions and has determined no material uncertain tax positions exist at December 31, 2016 2015. The Company generates research and development credits in the United Kingdom which are refundable if a current year loss is incurred. In the United Kingdom for the year ended December 31, 2016,

Note 13 - Intellectual Property

Note 13 - Intellectual Property - License Agreements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
License Agreements [Text Block]	1 3 . Intellectual property—license agreements The Company entered into three TB November 2013. TB December 31, 2016 15 The Company incurs royalties under each existing license agreement, has incurred royalties under the Oxford Innovation license agreement, and will incur continuing payment obligations to Oxford Innovation that are treated as royalties in these financial statements, based on its product and service revenue. The aggregate royalty expense relating to the three $6.8 $5.1 $4.8 December 31, 2016, 2015 2014, $0.2 $0.2 $0.1 December 31, 2016, 2015 2014, December 31, 2016, 2015 2014, 8%, 8% 10%,

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]	1 4 . Employee benefit plans In the United States, the Company has adopted a defined contribution plan (the U.S. Plan) which qualifies under Section 401(k) 21 January 1, 2008. may July 1, 2016 $0.2 December 31, 2016. In the United Kingdom, the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue & Customs. The U.K. Plan allows all U.K. employees to contribute a minimum of 5% 5% $0.6 December 31, 2016, $0.7 December 31, 2015 $0.6 2014.

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	15 . Commitments and contingencies Operating leases At December 31, 2016, six 2017 2021. January 31, 2025 June 11, 2019. March 1, 2013, five August 2015, two October 31, 2020. 7,600 22,100 $36,000 $12,000 2016, $39,000 one five December 31, 2021. two five two 2016 22,000 18,000 2021, 2018. $412,000 $263,000 Future minimum lease payments required under the non-cancelable operating leases in effect as of December 31, 2016 (in thousands) December 31, 6 2017 $ 1,945 2018 1,852 2019 1,406 2020 1,126 2021 659 Thereafter 192 Total minimum lease payments $ 7,180 Rent expense is calculated on a straight-line basis over the term of the lease. Rent expense recognized under operating leases totaled $1.4 $0.9 $0.7 December 31, 2016, 2015 2014, Purchase commitments The Company has license agreements with third 13, Future minimum payments required under license agreements and supplier purchase obligations in effect as of December 31, 2016 (in thousands) License agreements Supplier purchase obligations Total 2017 $ 1,518 $ 4,189 $ 5,707 2018 1,512 447 1,959 2019 1,506 — 1,506 2020 25 — 25 2021 — — — Thereafter — — — Total minimum payments $ 4,561 $ 4,636 $ 9,197 Legal contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may may In accordance with its articles of association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may

Note 16 - Geographic Revenue an

Note 16 - Geographic Revenue and Long-lived Assets Distribution	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 6 . Geographic revenue and long-lived assets distribution The Company is domiciled in the United Kingdom and operates in three December 31, 2016 , 2015 2014 December 31, 2016 and 2015. Revenue Long-lived assets Year s ended December 31, As of December 31, (in thousands) 201 6 201 5 201 4 201 6 201 5 United States $ 49,462 $ 31,362 $ 22,537 $ 6,625 $ 5,051 United Kingdom 2,620 2,836 2,971 922 954 Europe & ROW (excluding United Kingdom) 4,368 4,231 4,248 139 170 Europe & ROW 6,988 7,067 7,219 1,061 1,124 Asia 29,628 24,353 19,749 107 109 Total $ 86,078 $ 62,782 $ 49,505 $ 7,793 $ 6,284 China represented approximately 44%, 46% 43% 2016, 2015 2014, 55%, 53% 54% 2016, 2015 2014,

Note 17 - Acquisition Activity

Note 17 - Acquisition Activity	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Business Combination Disclosure [Text Block]	17 . Acquisition activity Imugen, Inc. On July 1, 2016, The consideration for the acquisition of Imugen consisted of $22.2 $1.8 twelve 8 September 9, 2016. The acquisition of Imugen was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the third 2016. These provisional amounts have been finalized during the fourth 2016. The table below summarizes the purchase price of the Imugen acquisition and the fair value of identified assets acquired at the acquisition date (in thousands): Assets acquired: Property and equipment $ 655 In-process research and development 9,200 Technology - clinical 5,100 Customer relationships 2,700 Trademarks / trade names 1,900 Total assets acquired 19,555 Add: Goodwill 2,645 Total consideration transferred $ 22,200 On the date of the acquisition, the fair value of acquired intangible assets was determined to be $18.9 22%. 3 Goodwill of approximately $2.6 December 31, 2016 December 31, 2016. 15 During the year ended December 31, 2016, $475,000 Actual results of operations acquired from Imugen are included in the consolidated financial statements from the date of the acquisition, including revenues in the amount of $7.0 $730,000, Immunetics, Inc. On October 12, 2016, Total consideration consisted of $6.0 $6.0 three . Approximately $400,000 eighteen 3 $3.4 4.4%. 2 The acquisition of Immunetics was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the fourth 2016. , based upon their estimated fair values at the date of the business acquisition. These provisional amounts may one The Company paid approximately $655,000 Total consideration was (in thousands): Cash consideration $ 6,000 Estimated fair value of contingent consideration 3,444 Total consideration transferred $ 9,444 The table below summarizes the purchase price of the Immunetics acquisition and the fair value of identified assets acquired and liabilities assumed at the acquisition date (in thousands): Assets acquired: Cash $ 285 Accounts receivable, net 347 Inventory, net 420 Prepaid expenses and other assets 199 Property and equipment 787 In-process research and development 6,970 Customer relationships 400 Trade name 290 Technology – clinical 860 Grants 50 Total assets acquired 10,608 Liabilities assumed: Accounts payable (319 ) Accrued liabilities (739 ) Other liabilities (1,283 ) Total liabilities assumed (2,341 ) Net assets acquired 8,267 Add: Goodwill 1,177 Total consideration transferred $ 9,444 On the date of the acquisition, the fair value of acquired intangible assets was determined to be $8.6 21.6% 60.2%, 3 Goodwill of approximately $1.2 December 31, 2016 December 31, 2016. Actual results of operations acquired from Immunetics are included in the consolidated financial statements from the date of the acquisition, including revenues in the amount of $392,000 $813,000, Pro Forma Information (Unaudited) : January 1, 2015. Year Ended December 31, (in thousands, except share and per share data) 201 6 201 5 Total revenues $ 92,860 $ 75,622 Net loss $ (21,840 ) $ (25,281 ) Net loss per share—basic and diluted $ (0.98 ) $ (1.16 ) Weighted average shares outstanding—basic and diluted 22,353,713 21,781,933 Pro forma net loss for the year ended December 31, 2016, $2.7 Prior Year Acquisition Boulder Diagnostics, Inc. On July 31, 2014, The terms of the purchase agreement provided for an upfront payment of $1.7 $6.1 July 31, 2024. $400,000 $700,000 $500,000 first $1.5 $3.0 3 $1.2 15%. 2 The acquisition of Boulder was accounted for under the acquisition method of accounting and was finalized during the fourth 2014. Cash consideration $ 1,724 Estimated fair value of contingent consideration 1,247 Total consideration transferred $ 2,971 $183,200 The Company paid approximately $181,000 The following table summarizes the purchase price of the Boulder acquisition, the fair value of identified assets acquired and liabilities assumed at the acquisition date (in thousands): Assets acquired: Cash $ 8 Accounts receivable 15 Inventory 40 Prepaid expenses and other assets 12 Property and equipment 359 In-process research and development 2,627 Total assets acquired 3,061 Liabilities assumed: Accounts payable (97 ) Accrued liabilities (14 ) Other current liabilities (34 ) Total liabilities assumed (145 ) Net assets acquired 2,916 Add: goodwill 55 Total consideration transferred $ 2,971 On the date of the acquisition the fair value of IPR&D acquired was determined to be $2.6 ($1.8 $0.5 $0.3 15% 3 Goodwill and IPR&D are indefinite-lived intangible assets and are not amortized. Rather, they are reviewed for impairment at least annually. During the third 2015, $385,000 December 31, 2015. fourth 2016, $270,000 fourth 2016, $1.4 During the fourth 2016, $901,000. fourth 2016, $551,000 Actual results of operations of Boulder for 2014 $42,000 $396,000.

Note 18 - Subsequent Event

Note 18 - Subsequent Event	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	18. Effective February 24, 2017, 529,096 94,989 2013 first 2017.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of presentation, accounting principles and principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, and include the financial statements of Oxford Immunotec Global PLC, a company incorporated in England and Wales and its wholly-owned subsidiaries, collectively referred to as the Company. All intercompany accounts and transactions have been eliminated upon consolidation.
Segment Reporting, Policy [Policy Text Block]	Segment reporting The Company operates in one
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and that affect the reported amounts of revenue and expenditures during the reporting periods. Actual results could differ from those estimates and assumptions used.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The functional currency for Oxford Immunotec Global PLC is the U.S. Dollar. The functional currency for the Company’s operating subsidiaries are the Pound Sterling for Oxford Immunotec Limited, the U.S. Dollar for Oxford Immunotec Inc. and Immunetics, Inc., the Yen for Oxford Immunotec K.K., the Yuan for Oxford Immunotec (Shanghai) Medical Device Co. Ltd., the Euro for Boulder Diagnostics Europe GmbH and the Hong Kong Dollar for Oxford Immunotec Asia Limited. Revenue and expenses of foreign operations are translated into U.S. Dollars at the average rates of exchange during the year. Assets and liabilities of foreign operations are translated into U.S. Dollars at year-end rates. The Company reflects resulting translation gains or losses in accumulated other comprehensive income, which is a component of shareholders’ equity. The Company does not record tax provisions or benefits for the net changes in foreign currency translation adjustments, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries. Realized and unrealized foreign currency transaction gains or losses, arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies, are included in “Other income (expense)” in the consolidated statements of operations.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of risks In the year ended December 31, 2016, two 10% March 15% 14%
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents and restricted cash The Company considers all highly liquid investments purchased with maturities at acquisition of three The Company maintains its available cash balances in cash, money market funds primarily invested in U.S. government securities, and bank savings accounts in the United States, United Kingdom, Germany, Japan and Hong Kong. The Company maintains deposits in government insured financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Restricted cash relates to collateral for procurement cards issued by a U.S. commercial bank.
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Accounts receivable Accounts receivable are primarily amounts due from customers including hospitals, public health departments, commercial testing laboratories, distributors and universities in addition to third Accounts receivable are reported net of an allowance for uncollectible accounts. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management’s analysis of current and past due accounts, collection experience and other relevant information. The Company’s provision for uncollectible accounts is recorded as a bad debt expense and included in general and administrative expenses. Account balances are written-off against the allowance when it is probable that the receivable will not be recovered. Although the Company believes amounts provided are adequate, the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.
Inventory, Policy [Policy Text Block]	Inventory Inventory consists of finished goods and raw materials. The Company does not maintain work in progress balances as the nature of the manufacturing process does not allow for test kits to be left in a partially manufactured state. Inventory is removed at cost. Inventory is stated at the lower of cost or market. Cost is determined by the actual cost of components by batch plus estimated labor and overhead costs per unit. Market value is based on an estimated selling price less any costs expected to be incurred to completion and sale. The Company reviews the components of its inventory on a periodic basis for excess, obsolete or impaired inventory, and records a reserve for the identified items.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are stated at cost. Property and equipment includes specialized shipping containers provided to customers, in the United States, for transporting samples to the Company’s laboratory for testing. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three ten three
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition The Company derives product revenue from the sale of its diagnostic test kits and related accessories to a broad range of customers including hospitals, public health departments, commercial testing laboratories, importers and distributors. Product revenue is generally paid directly by the customer and is recognized on an accrual basis when the following revenue recognition criteria are met: (1) (2) (3) (4) No product return rights are extended to customers of the Company. The Company derives service revenue from tests performed on samples sent by customers to its diagnostic laboratories in the United States and the United Kingdom, and to contracted laboratories in other countries. Service revenue in the United Kingdom and revenue from direct bill customers in the United States are recognized on an accrual basis when the following revenue recognition criteria are met: (1) (2) (3) (4) In the United States, the Company also generates revenue from payments that are received from a variety of third third Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations.
Cost of Sales, Policy [Policy Text Block]	Cost of revenue: cost of product and cost of service Cost of product revenue consists primarily of costs incurred in the production process, including costs of raw materials and components, assembly labor and overhead, quality management, royalties paid under licensing agreements, the U.S. medical device excise tax and packaging and delivery costs. Cost of service revenue consists primarily of costs incurred in the operation of the Company’s diagnostic laboratories including labor and overhead, kit costs, quality management, consumables used in the testing process and packaging and delivery costs.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may may
Business Combinations Policy [Policy Text Block]	Business combinations For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods. When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third third
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and indefinite-lived intangible assets Goodwill Goodwill is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate that all, or a portion, of the carrying value of the reporting unit may two first 50%) first may Indefinite-lived intangible assets The Company’s indefinite-lived intangible assets consist of acquired in-process research and development, or IPR&D, related to the Company’s business combinations with Boulder, Imugen and Immunetics, which were recorded at fair value on the acquisition dates. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may first 50%) first may The determinations as to whether, and, if so, the extent to which, acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends. Definite-lived intangible assets Intangible assets include technology licenses which are capitalized and amortized over estimated useful lives (generally in the range of five twenty
Derivatives, Policy [Policy Text Block]	Derivative financial instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, interest rate or foreign currency risks. The Company reviews the terms of the shares it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as other income or expense. When equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first
Fair Value Measurement, Policy [Policy Text Block]	Fair value of financial instruments The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of December 31, 2016 2015, 2
Research and Development Expense, Policy [Policy Text Block]	Research and development expenses Research and development expenses include all costs associated with the development of the Company’s T-SPOT technology platform and potential future products including new diagnostic tests that utilize the T-SPOT technology platform and are charged to expense as incurred. In addition, with the acquisition of Boulder in 2014 2016,
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based compensation The Company accounts for share-based compensation arrangements with employees, officers and directors by recognizing compensation expense based on the grant date fair value of share-based transactions in the consolidated financial statements. Share-based compensation for options is based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for share options and recognized as expense on a straight-line basis over the requisite service period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility, expected term and forfeiture rates. The expected volatility rates are estimated based on the actual volatility of comparable public companies over a historical period equal in length to the expected term. The expected terms represent the average time that options are expected to be outstanding based on the midpoint between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses an expected dividend yield of zero Certain employees have been granted restricted share units, or RSUs, and restricted shares. The fair value of RSUs and restricted shares are calculated based on the closing sale price of the Company’s ordinary shares on the date of grant. The cumulative expense recognized for share-based transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit for a period represents the movement in cumulative expense recognized as of the beginning and end of that period. No expense is recognized for awards that do not ultimately vest. Where the terms of an equity award are modified, the minimum expense recognized is the expense as if the terms had not been modified if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based compensation, or is otherwise beneficial to the employee as measured at the date of modification. Where a share-based compensation award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph. Upon exercise, share options are redeemed for newly issued ordinary shares.
Income Tax, Policy [Policy Text Block]	Income taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and its financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company adheres to the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken, or expected to be taken, in a tax return. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% not December 31, 2016 2015.
Earnings Per Share, Policy [Policy Text Block]	Basic and diluted net loss per ordinary share Basic and diluted net loss per ordinary share is determined by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. As the Company reports net losses, outstanding share options, RSUs and restricted shares have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per ordinary share for each period are the same.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09, 2014 09, 2014 09 December 15, 2017. December 15, 2016. 2014 09 first 2018 2014 09 may In August 2014, 2014 15, Presentation of Financial Statements - Going Concern 2014 15. 2014 15 December 15, 2016 2014 15 one 2014 15 October 1, 2016 on its financial position, results of operations or related disclosures. In July 2015, 2015 11, Simplifying the Measurement of Inventory 2015 11. 2015 11 2015 11 December 15, 2016. 2015 11 2015 11 In February 2016, 2016 02, Leases 2016 02. 2016 02 December 15, 2018. 2016 02 may In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09. 2016 09 December 15, 2016. 2016 09 In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. 2016 13 may In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments 2016 15. 2016 15 December 15, 2017. 2016 15 may In October 2016, 2016 16, Income Taxes 2016 16. December 15, 2017, 2016 16 2016 16 In November 2016, 2016 18, Restricted Cash 2016 18. 2016 18 December 15, 2017, 2016 18 In January 2017, 2017 01, Business Combinations 2017 01. 2017 01 December 15, 2017, 2017 01 In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. 2017 04 may Under the U.S. Jumpstart our Business Startups Act, or the JOBS Act, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. The Company irrevocably elected not to avail itself of this exemption from new or revised accounting standards and, therefore, it is subject to the same new or revised accounting standards as public companies that are not emerging growth companies.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling The Company does not normally bill its service customers for shipping and handling charges. Charges relating to inbound and outbound freight costs are incurred by the Company and recorded within cost of service. The Company generally bills product customers for shipping and handling and records the customer payments as product revenue. The associated costs are recorded as cost of product sold.

Note 2 - Fair Value Measureme27

Note 2 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair v alue m easurements at December 31, 201 6 u sing (in thousands) December 31, 6 Quoted p rices in a ctive m arkets for i dentical a ssets Significant o ther observable nputs Significant u nobservable i nputs Liabilities: Contingent purchase price consideration $ 3,475 $ — $ — $ 3,475 Total $ 3,475 $ — $ — $ 3,475 Fair v alue m easurements at December 31, 201 5 u sing (in thousands) December 31, 5 Quoted p rices in a ctive m arkets for i dentical a ssets Significant o ther observable nputs Significant u nobservable i nputs Liabilities: Contingent purchase price consideration $ 1,293 $ — $ — $ 1,293 Total $ 1,293 $ — $ — $ 1,293
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) 201 6 Balance – beginning $ 1,293 Immunetics acquisition (Note 17) 3,444 Change in fair value of contingent purchase price consideration 244 Write-off of Boulder contingent purchase price consideration (1,452 ) Foreign currency adjustment (54 ) Balance – ending $ 3,475 (in thousands) 2015 Balance – beginning $ 1,218 Change in fair value of c ontingent purchase price consideration 202 Foreign currency adjustment (127 ) Balance – ending $ 1,293

Note 3 - Accounts Receivable,28

Note 3 - Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, (in thousands) 201 6 201 5 Accounts receivable $ 14,050 $ 7,372 Less allowance for uncollectible accounts receivable (785 ) (314 ) Accounts receivable, net $ 13,265 $ 7,058
Allowance for Credit Losses on Financing Receivables [Table Text Block]	December 31, (in thousands) 201 6 201 5 201 4 Balance at beginning of period $ (314 ) $ (114 ) $ (165 ) Provision for bad debt expense (471 ) (200 ) — Write-off, net of recoveries — — 51 Balance at end of period $ (785 ) $ (314 ) $ (114 )

Note 4 - Inventory, Net (Tables

Note 4 - Inventory, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, (in thousands) 201 6 201 5 Raw materials $ 4,928 $ 3,925 Finished goods 2,509 3,174 Inventory $ 7,437 $ 7,099

Note 5 - Property and Equipme30

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, (in thousands) 201 6 201 5 Laboratory equipment $ 5,971 $ 4,865 Leasehold improvements 3,199 2,783 Office equipment, furniture and fixtures 3,364 2,841 Software 1,479 1,172 Specialized shipping containers 2,655 2,177 Construction in progress 848 200 Property and equipment 17,516 14,038 Less accumulated depreciation (9,723 ) (7,754 ) Property and equipment, net $ 7,793 $ 6,284

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Goodwill [Table Text Block]	Balance at December 31, 2014 $ 50 Foreign currency adjustment (5 ) Balance at December 31, 2015 45 Imugen acquisition (Note 17) 2,645 Immunetics acquisition (Note 17) 1,177 Impairment charge – Boulder goodwill (43 ) Foreign currency adjustment (2 ) Balance at December 31, 2016 $ 3,822
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	As of December 31 , 2016 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Imugen in-process research and development Indefinite $ 9,200 $ — $ 9,200 Imugen technology - clinical 15 5,100 170 4,930 Imugen customer relationships 10 2,700 135 2,565 Imugen trademarks / trade names 16 1,900 59 1,841 Immunetics in-process research and development Indefinite 6,970 — 6,970 Immunetics technology – clinical 15 860 9 851 Immunetics customer relationships 5 - 11 400 11 389 Immunetics trade name 5 290 9 281 Immunetics grants 2 50 4 46 Other 5 - 10 632 518 114 Total $ 28,102 $ 915 $ 27,187 As of December 31, 2015 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Boulder in-process research and development Indefinite $ 1,782 $ — $ 1,782 Other 5 - 10 758 579 179 Total $ 2,540 $ 579 $ 1,961

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, (in thousands) 201 6 201 5 Employee related expenses $ 6,592 $ 4,478 Royalties 4,423 3,498 Clinical trials 1,135 442 Professional services 387 333 Sales and use taxes payable 155 193 Other accrued liabilities 1,590 1,005 Total accrued liabilities $ 14,282 $ 9,949

Note 8 - Loans Payable (Tables)

Note 8 - Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	(in thousands) Term Loan 2017 $ — 2018 1,667 2019 10,000 2020 10,000 2021 8,333 Thereafter — Total minimum payments $ 30,000

Note 10 - Share Option and Eq34

Note 10 - Share Option and Equity Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	201 6 201 5 201 4 Expected dividend yield (%) — — — Expected volatility (%) 43.70 44.11 46.87 Risk-free interest rate (%) 1.53 1.66 1.86 Expected life of option (years) 6.16 6.19 6.19 Weighted-average share price ($) 10.29 14.15 19.66 Weighted-average exercise price ($) 10.29 14.15 19.66 Model used Black-Scholes Model Black-Scholes Model Black-Scholes Model
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of ordinary shares WAEP Outstanding as of January 1, 2016 2,425,426 $ 9.03 Granted 749,964 10.29 Exercised (85,943 ) 0.82 Forfeited (239,667 ) 14.27 Outstanding as of December 31, 2016 2,849,780 9.15 Vested or expected to vest as of December 31, 2016 2,790,851 $ 9.08 Exercisable as of December 31, 2016 1,671,179 $ 6.81
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of ordinary shares WAFV Unvested balance as of January 1, 2016 366,739 $ 19.72 Granted 108,361 10.21 Cancelled (57,530 ) 16.17 Vested (88,105 ) 22.99 Unvested balance as of December 31, 2016 329,465 16.34
Schedule of Nonvested Share Activity [Table Text Block]	Number of shares Weighted- average grant date fair value Balance as of December 31, 2015 1,124,443 $ 6.53 Granted 749,964 4.53 Vested (479,295 ) 5.92 Forfeited (216,510 ) 6.08 Balance as of December 31, 2016 1,178,602 5.61
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	(in thousands) 2016 2015 201 4 Cost of revenue $ 57 $ 529 $ 330 Research and development 548 86 87 Sales and marketing 1,725 1,045 949 General and administrative 2,689 1,825 1,155 Total share-based compensation $ 5,019 $ 3,485 $ 2,521

Note 11 - Net Loss Per Ordina35

Note 11 - Net Loss Per Ordinary Share (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year ended December 31, ( $ i n thousands ) 201 6 201 5 201 4 Numerator: Net loss per ordinary share $ (22,349 ) $ (24,478 ) $ (22,174 ) Denominator: Weighted-average ordinary shares outstanding-basic 22,353,713 21,781,933 17,310,148 Dilutive effect of ordinary share equivalents resulting from ordinary share options, ordinary share warrants and preferred ordinary shares (as converted) — — — Weighted-average ordinary shares outstanding-diluted 22,353,713 21,781,933 17,310,148
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year ended December 31, 201 6 201 5 201 4 Options to purchase ordinary shares 1,065,655 1,108,240 1,194,612 Unvested restricted shares and RSUs 329,465 366,739 275,500

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	(in thousands) 201 6 201 5 201 4 Domestic (United Kingdom) $ (730 ) $ 1,400 $ (158 ) Foreign (United States) (25,393 ) (25,732 ) (21,862 ) Loss before income taxes $ (26,123 ) $ (24,332 ) $ (22,020 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	(in thousands) 201 6 201 5 20 14 Current: Federal $ — $ — $ — U.K. — — — Japan (85 ) (116 ) (119 ) China (12 ) — — State (51 ) (30 ) (35 ) Total current provision (148 ) (146 ) (154 ) Deferred: Federal 752 — — U.K. 2,630 — — State 540 — — Total deferred benefit 3,922 — — Income tax benefit (expense) 3,774 (146 ) (154 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	201 6 201 5 201 4 Income tax rate 20.0 % 20.3 % 21.5 % U.K. research and development credit 1.8 1.3 1.7 Other (2.1 ) (1.1 ) (1.2 ) Effect of foreign tax rate differential 16.8 10.7 17.9 Valuation allowance (22.1 ) (31.7 ) (40.6 ) Effective income tax rate 14.4 % (0.5 )% (0.7 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	(in thousands) 201 6 201 5 Deferred tax assets: Long term deferred tax assets: U.S. federal net operating losses $ 42,165 $ 32,095 State net operating loss (net of federal) 5,198 4,021 U.S. federal research and development credit 273 155 U.K. net operating loss 2,419 5,217 Share options 1,884 1,251 Accrued liabilities 526 177 State credits 85 — Other — 160 Total deferred tax assets 52,550 43,076 Valuation allowance (46,473 ) (43,076 ) Total deferred tax assets $ 6,077 $ — Deferred tax liabilities: Long term deferred tax liabilities: Other assets $ (29 ) $ — Intangible assets (3,418 ) — Total deferred tax liabilities $ (3,447 ) $ —
Summary of Valuation Allowance [Table Text Block]	(in thousands) 201 6 201 5 201 4 Beginning of year (January 1) $ 43,076 $ 35,361 $ 26,413 Increase in valuation allowance 3,397 7,715 8,948 End of year (December 31) $ 46,473 $ 43,076 $ 35,361

Note 15 - Commitments and Con37

Note 15 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(in thousands) December 31, 6 2017 $ 1,945 2018 1,852 2019 1,406 2020 1,126 2021 659 Thereafter 192 Total minimum lease payments $ 7,180
Schedule of Future Minimum Payments for License Agreements [Table Text Block]	(in thousands) License agreements Supplier purchase obligations Total 2017 $ 1,518 $ 4,189 $ 5,707 2018 1,512 447 1,959 2019 1,506 — 1,506 2020 25 — 25 2021 — — — Thereafter — — — Total minimum payments $ 4,561 $ 4,636 $ 9,197

Note 16 - Geographic Revenue 38

Note 16 - Geographic Revenue and Long-lived Assets Distribution (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Revenue Long-lived assets Year s ended December 31, As of December 31, (in thousands) 201 6 201 5 201 4 201 6 201 5 United States $ 49,462 $ 31,362 $ 22,537 $ 6,625 $ 5,051 United Kingdom 2,620 2,836 2,971 922 954 Europe & ROW (excluding United Kingdom) 4,368 4,231 4,248 139 170 Europe & ROW 6,988 7,067 7,219 1,061 1,124 Asia 29,628 24,353 19,749 107 109 Total $ 86,078 $ 62,782 $ 49,505 $ 7,793 $ 6,284

Note 17 - Acquisition Activity

Note 17 - Acquisition Activity (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Assets acquired: Property and equipment $ 655 In-process research and development 9,200 Technology - clinical 5,100 Customer relationships 2,700 Trademarks / trade names 1,900 Total assets acquired 19,555 Add: Goodwill 2,645 Total consideration transferred $ 22,200 Assets acquired: Cash $ 285 Accounts receivable, net 347 Inventory, net 420 Prepaid expenses and other assets 199 Property and equipment 787 In-process research and development 6,970 Customer relationships 400 Trade name 290 Technology – clinical 860 Grants 50 Total assets acquired 10,608 Liabilities assumed: Accounts payable (319 ) Accrued liabilities (739 ) Other liabilities (1,283 ) Total liabilities assumed (2,341 ) Net assets acquired 8,267 Add: Goodwill 1,177 Total consideration transferred $ 9,444 Assets acquired: Cash $ 8 Accounts receivable 15 Inventory 40 Prepaid expenses and other assets 12 Property and equipment 359 In-process research and development 2,627 Total assets acquired 3,061 Liabilities assumed: Accounts payable (97 ) Accrued liabilities (14 ) Other current liabilities (34 ) Total liabilities assumed (145 ) Net assets acquired 2,916 Add: goodwill 55 Total consideration transferred $ 2,971
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Cash consideration $ 6,000 Estimated fair value of contingent consideration 3,444 Total consideration transferred $ 9,444 Cash consideration $ 1,724 Estimated fair value of contingent consideration 1,247 Total consideration transferred $ 2,971
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended December 31, (in thousands, except share and per share data) 201 6 201 5 Total revenues $ 92,860 $ 75,622 Net loss $ (21,840 ) $ (25,281 ) Net loss per share—basic and diluted $ (0.98 ) $ (1.16 ) Weighted average shares outstanding—basic and diluted 22,353,713 21,781,933

Note 1 - Description of Busin40

Note 1 - Description of Business and Significant Accounting Policies (Details Textual) $ in Thousands	Oct. 12, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Number of Operating Segments		1
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Payments of Dividends		$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense		0	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued		$ 0	$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life		5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		20 years
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life		10 years
Software Development [Member]
Property, Plant and Equipment, Useful Life		3 years
Specialized Shipping Containers [Member]
Property, Plant and Equipment, Useful Life		3 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Number of Major Customers		2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Shanghai Fosun Long March Medical Science Co. Ltd. [Member]
Concentration Risk, Percentage		15.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Riken Genesis Co., Ltd. [Member]
Concentration Risk, Percentage		14.00%
Immunetics [Member]
Payments to Acquire Businesses, Gross	$ 6,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 6,000
Business Combination, Contingent Consideration Arrangement, Term of Milestone Achievement	3 years

Note 2 - Fair Value Measureme41

Note 2 - Fair Value Measurement (Details Textual) - USD ($)	Oct. 12, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure		$ 0	$ 0
Immunetics [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 6,000,000
Business Combination, Contingent Consideration Arrangement, Term of Milestone Achievement	3 years
Business Combination, Contingent Consideration, Liability	$ 3,400,000
Immunetics [Member] | Contingent Purchase Price Consideration [Member]
Fair Value Inputs, Discount Rate	4.40%
GoutiFind Assay [Member]
Contingent Consideration Arrangements, Liability, Write-off		901,000
SpiroFind Assay [Member]
Contingent Consideration Arrangements, Liability, Write-off		$ 551,000

Note 2 - Fair Value Measureme42

Note 2 - Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Contingent purchase price consideration	$ 2,593	$ 1,293
Total	3,475	1,293
Fair Value, Inputs, Level 1 [Member]
Contingent purchase price consideration
Total
Fair Value, Inputs, Level 2 [Member]
Contingent purchase price consideration
Total
Fair Value, Inputs, Level 3 [Member]
Contingent purchase price consideration	3,475	1,293
Total	$ 3,475	$ 1,293

Note 2 - Fair Value Measureme43

Note 2 - Fair Value Measurement - Changes in the Fair Value of the Company's Level 3 Financial Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Balance	$ 1,293	$ 1,218
Immunetics acquisition (Note 17)	3,444
Change in fair value of contingent purchase price consideration	244	202
Write-off of Boulder contingent purchase price consideration	(1,452)
Foreign currency adjustment	(54)	(127)
Balance	$ 3,475	$ 1,293

Note 3 - Accounts Receivable,44

Note 3 - Accounts Receivable, Net - Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable	$ 14,050	$ 7,372
Less allowance for uncollectible accounts receivable	(785)	(314)
Accounts receivable, net	$ 13,265	$ 7,058

Note 3 - Accounts Receivable,45

Note 3 - Accounts Receivable, Net - Activity for the Allowance for Uncollectible Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Balance at beginning of period	$ (785)	$ (314)	$ (114)	$ (165)
Provision for bad debt expense	(471)	(200)
Write-off, net of recoveries			$ 51

Note 4 - Inventory, Net - Inven

Note 4 - Inventory, Net - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Raw materials	$ 4,928	$ 3,925
Finished goods	2,509	3,174
Inventory	$ 7,437	$ 7,099

Note 5 - Property and Equipme47

Note 5 - Property and Equipment, Net (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Depreciation	$ 2.6	$ 2	$ 1.7
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Software Development [Member]
Property, Plant and Equipment, Useful Life	3 years
Specialized Shipping Containers [Member]
Property, Plant and Equipment, Useful Life	3 years

Note 5 - Property and Equipme48

Note 5 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 17,516	$ 14,038
Less accumulated depreciation	(9,723)	(7,754)
Property and equipment, net	7,793	6,284
Laboratory Equipment [Member]
Property and equipment, gross	5,971	4,865
Leasehold Improvements [Member]
Property and equipment, gross	3,199	2,783
Office Equipment Furniture and Fixtures [Member]
Property and equipment, gross	3,364	2,841
Software and Software Development Costs [Member]
Property and equipment, gross	1,479	1,172
Specialized Shipping Containers [Member]
Property and equipment, gross	2,655	2,177
Construction in Progress [Member]
Property and equipment, gross	$ 848	$ 200

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		13 years
Amortization of Intangible Assets		$ 435,000	$ 92,000	$ 43,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 1,000,000	1,000,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	900,000	900,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	16,170,000	16,170,000	1,782,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	900,000	900,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	900,000	900,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	900,000	900,000
In Process Research and Development, Indefinite Lived [Member] | Imugen [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	9,200,000	9,200,000
In Process Research and Development, Indefinite Lived [Member] | Immunetics [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	6,970,000	$ 6,970,000
In Process Research and Development, Indefinite Lived [Member] | Boulder Diagnostics Inc [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)			$ 1,782,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 1,400,000

Note 6 - Goodwill and Acquired

Note 6 - Goodwill and Acquired Intangible Assets - Changes in Carrying Amount of Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Balance		$ 45,000	$ 50,000
Foreign currency adjustment		(2,000)	(5,000)
Balance	$ 3,822,000	3,822,000	$ 45,000
Impairment charge – Boulder goodwill		(43,000)
Imugen [Member]
Imugen acquisition (Note 17)		2,645,000
Impairment charge – Boulder goodwill		0
Immunetics [Member]
Imugen acquisition (Note 17)		$ 1,177,000
Impairment charge – Boulder goodwill	$ 0

Note 6 - Goodwill and Acquire51

Note 6 - Goodwill and Acquired Intangible Assets - Schedule of Acquired Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Gross carrying amount	$ 16,170,000	$ 1,782,000
Gross carrying amount	28,102,000
Accumulated Amortization	915,000	579,000
Net carrying amount	27,187,000	1,961,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 16,170,000	1,782,000
Gross carrying amount		2,540,000
Minimum [Member]
Amortization period (Year)	5 years
Maximum [Member]
Amortization period (Year)	20 years
Other Intangible Assets [Member]
Gross carrying amount	$ 632,000	758,000
Accumulated Amortization	518,000	579,000
Net carrying amount	$ 114,000	$ 179,000
Other Intangible Assets [Member] | Minimum [Member]
Amortization period (Year)	5 years	5 years
Other Intangible Assets [Member] | Maximum [Member]
Amortization period (Year)	10 years	10 years
Imugen [Member] | Technology-Based Intangible Assets [Member]
Amortization period (Year)	15 years
Gross carrying amount	$ 5,100,000
Accumulated Amortization	170,000
Net carrying amount	$ 4,930,000
Imugen [Member] | Customer Relationships [Member]
Amortization period (Year)	10 years
Gross carrying amount	$ 2,700,000
Accumulated Amortization	135,000
Net carrying amount	$ 2,565,000
Imugen [Member] | Trademarks and Trade Names [Member]
Amortization period (Year)	16 years
Gross carrying amount	$ 1,900,000
Accumulated Amortization	59,000
Net carrying amount	$ 1,841,000
Immunetics [Member] | Technology-Based Intangible Assets [Member]
Amortization period (Year)	15 years
Gross carrying amount	$ 860,000
Accumulated Amortization	9,000
Net carrying amount	851,000
Immunetics [Member] | Customer Relationships [Member]
Gross carrying amount	400,000
Accumulated Amortization	11,000
Net carrying amount	$ 389,000
Immunetics [Member] | Customer Relationships [Member] | Minimum [Member]
Amortization period (Year)	5 years
Immunetics [Member] | Customer Relationships [Member] | Maximum [Member]
Amortization period (Year)	11 years
Immunetics [Member] | Trade Names [Member]
Amortization period (Year)	5 years
Gross carrying amount	$ 290,000
Accumulated Amortization	9,000
Net carrying amount	$ 281,000
Immunetics [Member] | Grants [Member]
Amortization period (Year)	2 years
Gross carrying amount	$ 50,000
Accumulated Amortization	4,000
Net carrying amount	46,000
In Process Research and Development, Indefinite Lived [Member] | Imugen [Member]
Gross carrying amount	9,200,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	9,200,000
In Process Research and Development, Indefinite Lived [Member] | Boulder Diagnostics Inc [Member]
Gross carrying amount		$ 1,782,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)		$ 1,782,000
In Process Research and Development, Indefinite Lived [Member] | Immunetics [Member]
Gross carrying amount	6,970,000
Accumulated Amortization
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 6,970,000

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Employee related expenses	$ 6,592	$ 4,478
Royalties	4,423	3,498
Clinical trials	1,135	442
Professional services	387	333
Sales and use taxes payable	155	193
Other accrued liabilities	1,590	1,005
Total accrued liabilities	$ 14,282	$ 9,949

Note 8 - Loans Payable (Details

Note 8 - Loans Payable (Details Textual)	Oct. 04, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jun. 30, 2013USD ($)a
Cost to Build Facility, Percentage				80.00%
Loans Payable, Current		$ 84,000	$ 79,000
Loans Payable, Noncurrent		29,601,000	$ 386,000
MidCap Agreement [Member] | MidCap Financial [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 40,000,000
Long-term Debt		30,000,000
Debt Agreement, Additional Increase	10
Debt Agreement, Maximum Borrowing Capacity, Including Additional Increase	$ 60,000,000
Debt Agreement, Final Commitment Fee Percentage	6.00%
MidCap Agreement [Member] | MidCap Financial [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 10,000,000
Line of Credit Facility, Expiration Period	5 years
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Line of Credit Facility, Early Termination, Commitment Fee Percentage, First Year	3.00%
Line of Credit Facility, Early Termination, Commitment Fee Percentage, Second Year	2.00%
Line of Credit Facility, Early Termination, Commitment Fee Percentage, Third Year and Thereafter	1.00%
Long-term Line of Credit		0
MidCap Agreement [Member] | MidCap Financial [Member] | London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member]
Debt Instrument, Basis Spread on Variable Rate	4.45%
MidCap Agreement [Member] | MidCap Financial [Member] | Term Loan [Member]
Long-term Debt		$ 30,000,000
Debt Instrument, Term	5 years
Debt Instrument, Periodic Payment, Term	2 years
Debt Instrument, Periodic Payment, Term, Potential Extension	4 years
Debt Agreement, Exit Fee, Percentage		6.00%
Interest Expense		$ 1,800,000
MidCap Agreement [Member] | MidCap Financial [Member] | Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	7.60%
Lease Incentive [Member]
Loans Payable, Current		71,000
Loans Payable, Noncurrent		$ 236,000
Marlborough, Massachusetts [Member]
Area of Real Estate Property | a				14,500
Incentive from Lessor				$ 582,000

Note 8 - Loans Payable - Future

Note 8 - Loans Payable - Future Minimum Payments (Details) - MidCap Agreement [Member] - MidCap Financial [Member]	Dec. 31, 2016USD ($)
Total minimum payments	$ 30,000,000
Term Loan [Member]
2,017
2,018	1,667,000
2,019	10,000,000
2,020	10,000,000
2,021	8,333,000
Thereafter
Total minimum payments	$ 30,000,000

Note 9 - Share Capital (Details

Note 9 - Share Capital (Details Textual) $ / shares in Units, $ in Millions	Jan. 30, 2015USD ($)	Jan. 29, 2015£ / sharesshares	Jan. 29, 2015£ / sharesshares	Dec. 31, 2016£ / sharesshares	Dec. 31, 2015£ / sharesshares	Dec. 31, 2014shares	Jan. 29, 2015$ / sharesshares
Common Stock, Par or Stated Value Per Share | £ / shares		£ 0.006705	£ 0.006705	£ 0.006705	£ 0.006705
Time Period for Underwriters to Exercise Share Grants from Date of Prospectus			30 days
Additional Shares Granted to Underwritten in Private Placement		638,297	638,297				638,297
Proceeds from Issuance of Private Placement, Gross | $	$ 57.5
Proceeds from Issuance of Private Placement | $	$ 53.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				85,943	41,222	65,054
Common Stock, Shares Authorized				36,183,293	36,183,293
Common Stock, Shares, Issued				22,635,431	22,549,488
Common Stock, Shares, Outstanding				22,635,431	22,549,488
Underwriters [Member]
Shares Issued, Price Per Share | $ / shares							$ 11.045
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		4,255,319
Shares Issued, Price Per Share | $ / shares							$ 11.75

Note 10 - Share Option and Eq56

Note 10 - Share Option and Equity Incentive Plan (Details Textual) - USD ($)	12 Months Ended			84 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2014	Nov. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.53	$ 6.33	$ 9.32
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeiture Rate	5.00%	5.00%	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 19,200,000	$ 12,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 15,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	85,943	41,222	65,054
Proceeds from Stock Options Exercised	$ 76,000	$ 20,000	$ 14,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	1,000,000	500,000	900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	2,900,000	1,900,000	1,000,000
Payments of Dividends	0
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 5,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 146 days
Allocated Share-based Compensation Expense	$ 3,200,000	2,400,000	1,600,000
Restricted Stock Units (RSUs) [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 3,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 328 days
Allocated Share-based Compensation Expense	$ 1,800,000	$ 1,100,000	$ 900,000
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					2,684,563
Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase, Percentage of Shares Outstanding					4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,004,074
2013 Plan [Member] | Until Second Aniversary of Vesting Start Date of Employee First Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				0.00%
2013 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Second Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	40.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Third Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	30.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Fourth Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	30.00%

Note 10 - Share Option and Eq57

Note 10 - Share Option and Equity Incentive Plan - Valuation Assumptions, Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Expected dividend yield (%)	0.00%
Weighted-average exercise price ($) (in dollars per share)	$ 10.29
Employee Stock Option [Member]
Expected dividend yield (%)
Expected volatility (%)	43.70%	44.11%	46.87%
Risk-free interest rate (%)	1.53%	1.66%	1.86%
Expected life of option (years) (Year)	6 years 58 days	6 years 69 days	6 years 69 days
Weighted-average share price ($) (in dollars per share)	$ 10.29	$ 14.15	$ 19.66
Weighted-average exercise price ($) (in dollars per share)	$ 10.29	$ 14.15	$ 19.66
Model used	Black-Scholes Model	Black-Scholes Model	Black-Scholes Model

Note 10 - Share Option and Eq58

Note 10 - Share Option and Equity Incentive Plan - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of share options outstanding (in shares)	2,425,426
Number of share options outstanding, weighted average exercise price (in dollars per share)	$ 9.03
Number of share options granted (in shares)	749,964
Weighted-average exercise price ($) (in dollars per share)	$ 10.29
Number of share options exercised (in shares)	(85,943)	(41,222)	(65,054)
Number of share options exercised, weighted average exercise price (in dollars per share)	$ 0.82
Number of share options forfeited (in shares)	(239,667)
Number of share options forfeited, weighted average exercise price (in dollars per share)	$ 14.27
Number of share options oustanding (in shares)	2,849,780	2,425,426
Number of share options oustanding, weighted average exercise price (in dollars per share)	$ 9.15	$ 9.03
Number of share options vested or expected to vest (in shares)	2,790,851
Number of share options vested or expected to vest, weighted average exercise price (in dollars per share)	$ 9.08
Number of share options exercisable (in shares)	1,671,179
Number of share options exercisable, weighted average exercise price (in dollars per share)	$ 6.81

Note 10 - Share Option and Eq59

Note 10 - Share Option and Equity Incentive Plan - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Unvested balance (in shares) | shares	366,739
Unvested balance, weighted average exercise price (in dollars per share) | $ / shares	$ 19.72
Granted (in shares) | shares	108,361
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 10.21
Cancelled (in shares) | shares	(57,530)
Cancelled, weighted average exercise price (in dollars per share) | $ / shares	$ 16.17
Vested (in shares) | shares	(88,105)
Vested, weighted average exercise price (in dollars per share) | $ / shares	$ 22.99
Unvested balance (in shares) | shares	329,465
Unvested balance, weighted average exercise price (in dollars per share) | $ / shares	$ 16.34

Note 10 - Share Option and Eq60

Note 10 - Share Option and Equity Incentive Plan - Unvested Share Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of unvested share options outstanding (in shares)	1,124,443
Number of unvested share options outstanding, weighted-average grant date fair value (in dollars per share)	$ 6.53
Number of share options granted (in shares)	749,964
Number of unvested share options granted, weighted-average grant date fair value (in dollars per share)	$ 4.53	$ 6.33	$ 9.32
Number of unvested share options vested (in shares)	(479,295)
Number of unvested share options vested, weighted-average grant date fair value (in dollars per share)	$ 5.92
Number of unvested share options forfeited (in shares)	(216,510)
Number of unvested share options forfeited, weighted-average grant date fair value (in dollars per share)	$ 6.08
Number of unvested share options outstanding (in shares)	1,178,602	1,124,443
Number of unvested share options outstanding, weighted-average grant date fair value (in dollars per share)	$ 5.61	$ 6.53

Note 10 - Share Option and Eq61

Note 10 - Share Option and Equity Incentive Plan - Expense Recognized During the Year Related to Share-based Compensation Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based compensation	$ 5,019	$ 3,485	$ 2,521
Cost of Revenue [Member]
Share-based compensation	57	529	330
Research and Development Expense [Member]
Share-based compensation	548	86	87
Selling and Marketing Expense [Member]
Share-based compensation	1,725	1,045	949
General and Administrative Expense [Member]
Share-based compensation	$ 2,689	$ 1,825	$ 1,155

Note 11 - Net Loss Per Ordina62

Note 11 - Net Loss Per Ordinary Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net loss per ordinary share	$ (22,349)	$ (24,478)	$ (22,174)
Weighted-average ordinary shares outstanding-basic (in shares)	22,353,713	21,781,933	17,310,148
Dilutive effect of ordinary share equivalents resulting from ordinary share options, ordinary share warrants and preferred ordinary shares (as converted) (in shares)
Weighted-average ordinary shares outstanding-diluted (in shares)	22,353,713	21,781,933	17,310,148

Note 11 - Net Loss Per Ordina63

Note 11 - Net Loss Per Ordinary Share - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option [Member]
Antidilutive securities (in shares)	1,065,655	1,108,240	1,194,612
Restricted Stock and RSUs [Member]
Antidilutive securities (in shares)	329,465	366,739	275,500

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Apr. 01, 2020	Apr. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective UK Corporate Tax Rate			20.00%	20.30%	21.50%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			34.00%	34.00%	34.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent			17.00%
Deferred Tax Assets, Net of Valuation Allowance			$ 6,077
Research Tax Credit Carryforward [Member]
Income Tax Credits and Adjustments			0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards			$ 112,500	$ 85,800
Her Majesty's Revenue and Customs (HMRC) [Member]
Effective UK Corporate Tax Rate			20.00%	20.30%	21.50%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent			14.40%	(0.50%)	(0.70%)
Operating Loss Carryforwards			$ 14,200	$ 29,000
Deferred Tax Assets, Net of Valuation Allowance			2,600
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards			$ 125,300	$ 95,500
Scenario, Forecast [Member]
Effective UK Corporate Tax Rate	17.00%	19.00%
Earliest Tax Year [Member]
Open Tax Year			2,013
Latest Tax Year [Member]
Open Tax Year			2,016

Note 12 - Income Taxes - Compon

Note 12 - Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Domestic (United Kingdom)	$ (730)	$ 1,400	$ (158)
Foreign (United States)	(25,393)	(25,732)	(21,862)
Loss before income taxes	$ (26,123)	$ (24,332)	$ (22,020)

Note 12 - Income Taxes - Comp66

Note 12 - Income Taxes - Components for the Income Tax (Expense) Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Federal
State	(51)	(30)	(35)
Total current provision	(148)	(146)	(154)
Federal	752
U.K.	2,630
State	540
Total deferred benefit	3,922
Income tax benefit (expense)	3,774	(146)	(154)
Her Majesty's Revenue and Customs (HMRC) [Member]
Foreign
National Tax Agency, Japan [Member]
Foreign	(85)	(116)	(119)
State Administration of Taxation, China [Member]
Foreign	$ (12)

Note 12 - Income Taxes - Effect

Note 12 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income tax rate	20.00%	20.30%	21.50%
Effective income tax rate	17.00%
Her Majesty's Revenue and Customs (HMRC) [Member]
Income tax rate	20.00%	20.30%	21.50%
U.K. research and development credit	1.80%	1.30%	1.70%
Other	(2.10%)	(1.10%)	(1.20%)
Effect of foreign tax rate differential	16.80%	10.70%	17.90%
Valuation allowance	(22.10%)	(31.70%)	(40.60%)
Effective income tax rate	14.40%	(0.50%)	(0.70%)

Note 12 - Income Taxes - Deferr

Note 12 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share options	$ 1,884	$ 1,251
Accrued liabilities	526	177
State credits	85
Other		160
Total deferred tax assets	52,550	43,076
Valuation allowance	(46,473)	(43,076)	$ (35,361)	$ (26,413)
Total deferred tax assets	6,077
Other assets	(29)
Intangible assets	(3,418)
Total deferred tax liabilities	(3,447)
State and Local Jurisdiction [Member]
State net operating loss (net of federal)	5,198	4,021
Internal Revenue Service (IRS) [Member]
U.S. federal net operating losses	42,165	32,095
U.S. federal research and development credit	273	155
Her Majesty's Revenue and Customs (HMRC) [Member]
U.K. net operating loss	2,419	$ 5,217
Total deferred tax assets	$ 2,600

Note 12 - Income Taxes - Defe69

Note 12 - Income Taxes - Deferred Tax Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Beginning of year (January 1)	$ 43,076	$ 35,361	$ 26,413
Increase in valuation allowance	3,397	7,715	8,948
End of year (December 31)	$ 46,473	$ 43,076	$ 35,361

Note 13 - Intellectual Proper70

Note 13 - Intellectual Property - License Agreements (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Number of License Agreements	3
Royalty Expense	$ 6.8	$ 5.1	$ 4.8
License Costs	$ 0.2	$ 0.2	$ 0.1
Aggregate Royalty Rate, Percent of Gross Product and Service Revenue	8.00%	8.00%	10.00%

Note 14 - Employee Benefit Pl71

Note 14 - Employee Benefit Plans (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
The U.K. Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.6	$ 0.7	$ 0.6
Defined Contribution Plan Minimum Annual Contributions per Employee, Percent	5.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	5.00%
US Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.2

Note 15 - Commitments and Con72

Note 15 - Commitments and Contingencies (Details Textual)	Mar. 01, 2013	Aug. 31, 2015ft²	Dec. 31, 2016USD ($)ft²	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jul. 31, 2015ft²
Number of Non-cancelable Operating Leases			6
Number of Laboratories Acquired			2
Operating Leases, Rent Expense			$ 1,400,000	$ 900,000	$ 700,000
Corporate Headquarters [Member]
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years
Office Space in Malborough, Massachusetts [Member]
Lessee Leasing Arrangements, Operating Leases, Renewal Term		2 years
Area of Leased Space | ft²		22,100				7,600
Lessee Leasing Arrangements, Operating Leases, Optional Extension of Contract			5 years
Office Space in Malborough, Massachusetts [Member] | Office Expansion [Member]
Operating Leases, Rent Expense, Per Month				12,000
Office Space in Malborough, Massachusetts [Member] | Minimum [Member]
Operating Leases, Rent Expense, Per Month				36,000
Office Space in Malborough, Massachusetts [Member] | Maximum [Member]
Operating Leases, Rent Expense, Per Month				$ 39,000
Laboratory Space in Memphis, Tennessee [Member]
Lessee Leasing Arrangements, Operating Leases, Optional Extension of Contract			5 years
Norwood Lease [Member]
Area of Leased Space | ft²			22,000
Operating Leases, Rent Expense			$ 412,000
Boston Lease [Member]
Area of Leased Space | ft²			18,000
Operating Leases, Rent Expense			$ 263,000

Note 15 - Commitments and Con73

Note 15 - Commitments and Contingencies - Future Minimum Lease Payments under the Non-cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2016USD ($)
2,017	$ 1,945
2,018	1,852
2,019	1,406
2,020	1,126
2,021	659
Thereafter	192
Total minimum lease payments	$ 7,180

Note 15 - Commitments and Con74

Note 15 - Commitments and Contingencies - Future Minimum Payments Required Under the License Agreements (Details) $ in Thousands	Dec. 31, 2016USD ($)
2,017	$ 1,518
2,017	4,189
2,017	5,707
2,018	1,512
2,018	447
2,018	1,959
2,019	1,506
2,019
2,019	1,506
2,020	25
2,020
2,020	25
2,021
2,021
2,021
License agreements, future minimum payments due thereafter
Purchase obligations, future minimum payments due thereafter
License agreements and purchase obligations, future minimum payments due thereafter
License agreements, future minimum payments due	4,561
Purchase obligations, future minimum payments due	4,636
License agreements and purchase obligations, future minimum payments due	$ 9,197

Note 16 - Geographic Revenue 75

Note 16 - Geographic Revenue and Long-lived Assets Distribution (Details Textual)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Geographies in which the Company Operates	3
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | CHINA
Concentration Risk, Percentage	44.00%	46.00%	43.00%
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | JAPAN
Concentration Risk, Percentage	55.00%	53.00%	54.00%

Note 16 - Geographic Revenue 76

Note 16 - Geographic Revenue and Long-lived Assets Distribution - Revenue and Long-lived Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue by geographic area	$ 86,078	$ 62,782	$ 49,505
Long-lived assets by geographic area	7,793	6,284
UNITED STATES
Revenue by geographic area	49,462	31,362	22,537
Long-lived assets by geographic area	6,625	5,051
UNITED KINGDOM
Revenue by geographic area	2,620	2,836	2,971
Long-lived assets by geographic area	922	954
Europe and ROW, Excluding U.K. [Member]
Revenue by geographic area	4,368	4,231	4,248
Long-lived assets by geographic area	139	170
European Union [Member]
Revenue by geographic area	6,988	7,067	7,219
Long-lived assets by geographic area	1,061	1,124
Asia [Member]
Revenue by geographic area	29,628	24,353	$ 19,749
Long-lived assets by geographic area	$ 107	$ 109

Note 17 - Acquisition Activit77

Note 17 - Acquisition Activity (Details Textual) - USD ($)	Oct. 12, 2016	Jul. 01, 2016	Jul. 31, 2014	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill				$ 3,822,000	$ 3,822,000	$ 3,822,000	$ 45,000	$ 50,000
Payments to Acquire Businesses, Net of Cash Acquired						27,515,000		1,716,000
Goodwill, Impairment Loss						43,000
GoutiFind Assay [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)					270,000
GoutiFind Assay [Member]
Contingent Consideration Arrangements, Liability, Write-off					901,000
SpiroFind Assay [Member]
Contingent Consideration Arrangements, Liability, Write-off					551,000
Imugen [Member]
Payments to Acquire Businesses, Gross		$ 22,200,000
Business Combination, Portion of Purchase Price Held in Escrow		1,800,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		18,900,000
Goodwill		$ 2,645,000
Goodwill, Tax Deduction, Period		15 years
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual						7,000,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual						730,000
Goodwill, Impairment Loss						0
Imugen [Member] | In Process Research and Development, Indefinite Lived [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 9,200,000
Imugen [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs						475,000
Imugen [Member] | Intangible Assets [Member]
Fair Value Inputs, Discount Rate		22.00%
Immunetics [Member]
Payments to Acquire Businesses, Gross	$ 6,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	8,600,000
Goodwill	1,177,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	392,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	813,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 6,000,000
Business Combination, Contingent Consideration Arrangement, Term of Milestone Achievement	3 years
Business Combination, Portion of Purchase Price Held for Indemnification Claims	$ 400,000
Business Combination, Contingent Consideration, Liability	3,400,000
Goodwill, Impairment Loss				$ 0
Immunetics [Member] | In Process Research and Development, Indefinite Lived [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 6,970,000
Immunetics [Member] | Contingent Purchase Price Consideration [Member]
Fair Value Inputs, Discount Rate	4.40%
Immunetics [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs	$ 655,000
Immunetics [Member] | Intangible Assets [Member] | Minimum [Member]
Fair Value Inputs, Discount Rate	21.60%
Immunetics [Member] | Intangible Assets [Member] | Maximum [Member]
Fair Value Inputs, Discount Rate	60.20%
Imugen and Immunetics [Member]
Business Combination, Acquisition Related Costs and Accelerated Stock-based Compensation Costs						$ 2,700,000
Boulder Diagnostics Inc [Member]
Payments to Acquire Businesses, Gross			$ 1,724,000
Goodwill			55,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								42,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual								$ 396,000
Business Combination, Contingent Consideration, Liability			1,200,000
Payments to Acquire Businesses, Net of Cash Acquired			1,700,000
Restricted Cash and Cash Equivalents			183,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets			$ 2,627,000
Boulder Diagnostics Inc [Member] | In Process Research and Development Member 1 [Member]
Fair Value Inputs, Discount Rate			15.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets			$ 2,600,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)							$ 385,000
Boulder Diagnostics Inc [Member] | Lyme Disease Assay [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets			1,800,000
Boulder Diagnostics Inc [Member] | Biologics for Autoimmune Disease Assay [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets			500,000
Boulder Diagnostics Inc [Member] | Gout Assay [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets			300,000
Boulder Diagnostics Inc [Member] | In Process Research and Development, Indefinite Lived [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)					$ 1,400,000
Boulder Diagnostics Inc [Member] | Milestone Payments [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			6,100,000
Boulder Diagnostics Inc [Member] | Milestone Payments for Completion of Studies Related to Acquired Technologies [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			400,000
Boulder Diagnostics Inc [Member] | Milestone Payments for Development of Diagnostic Test Kits [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			700,000
Boulder Diagnostics Inc [Member] | Milestone Payments for the First Patient Enrolled in an Institution Review Board Approved Study [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			500,000
Boulder Diagnostics Inc [Member] | Milestone Payments for Issuance of Patents [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			1,500,000
Boulder Diagnostics Inc [Member] | Milestone Payments for Approvals or Clearance by the FDA [Member}
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			3,000,000
Boulder Diagnostics Inc [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs			$ 181,000

Note 17 - Acquisition Activit78

Note 17 - Acquisition Activity - Fair Value of Identified Assets Acquired (Details) - USD ($)	Dec. 31, 2016	Oct. 12, 2016	Jul. 01, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 31, 2014
Goodwill	$ 3,822,000			$ 45,000	$ 50,000
Imugen [Member]
Property and equipment			$ 655,000
Intangible assets			18,900,000
Total assets acquired			19,555,000
Goodwill			2,645,000
Total consideration transferred			22,200,000
Property and equipment			655,000
Imugen [Member] | Technology-Based Intangible Assets [Member]
Intangible assets			5,100,000
Imugen [Member] | Customer Relationships [Member]
Intangible assets			2,700,000
Imugen [Member] | Trademarks and Trade Names [Member]
Intangible assets			1,900,000
Imugen [Member] | In Process Research and Development, Indefinite Lived [Member]
Intangible assets			$ 9,200,000
Immunetics [Member]
Property and equipment		$ 787,000
Intangible assets		8,600,000
Total assets acquired		10,608,000
Goodwill		1,177,000
Total consideration transferred		9,444,000
Cash		285,000
Accounts receivable, net		347,000
Inventory, net		420,000
Prepaid expenses and other assets		199,000
Accounts payable		(319,000)
Accrued liabilities		(739,000)
Other liabilities		(1,283,000)
Total liabilities assumed		(2,341,000)
Net assets acquired		8,267,000
Property and equipment		787,000
Accounts payable		(319,000)
Accrued liabilities		(739,000)
Immunetics [Member] | Technology-Based Intangible Assets [Member]
Intangible assets		860,000
Immunetics [Member] | Customer Relationships [Member]
Intangible assets		400,000
Immunetics [Member] | Trade Names [Member]
Intangible assets		290,000
Immunetics [Member] | Grants [Member]
Intangible assets		50,000
Immunetics [Member] | In Process Research and Development, Indefinite Lived [Member]
Intangible assets		$ 6,970,000
Boulder Diagnostics Inc [Member]
Property and equipment						$ 359,000
Total assets acquired						3,061,000
Goodwill						55,000
Total consideration transferred						2,971,000
Cash						8,000
Accounts receivable, net						15,000
Inventory, net						40,000
Prepaid expenses and other assets						12,000
Accounts payable						(97,000)
Accrued liabilities						(14,000)
Other liabilities						(34,000)
Total liabilities assumed						(145,000)
Net assets acquired						2,916,000
Property and equipment						359,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets						2,627,000
Accounts payable						(97,000)
Accrued liabilities						$ (14,000)

Note 17 - Acquisition Activit79

Note 17 - Acquisition Activity - Business Acquisition, Consideration Transferred (Details) - USD ($) $ in Thousands	Oct. 12, 2016	Jul. 31, 2014
Immunetics [Member]
Cash consideration	$ 6,000
Estimated fair value of contingent consideration	3,444
Total consideration transferred	$ 9,444
Boulder Diagnostics Inc [Member]
Cash consideration		$ 1,724
Estimated fair value of contingent consideration		1,247
Total consideration transferred		$ 2,971

Note 17 - Acquisition Activit80

Note 17 - Acquisition Activity - Unaudited Pro Forma Condensed Consolidated Statement of Operations (Details) - Imugen and Immunetics [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total revenues	$ 92,860	$ 75,622
Net loss	$ (21,840)	$ (25,281)
Net loss per share—basic and diluted (in dollars per share)	$ (0.98)	$ (1.16)
Weighted average shares outstanding—basic and diluted (in shares)	22,353,713	21,781,933

Note 18 - Subsequent Event (Det

Note 18 - Subsequent Event (Details Textual) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		749,964
Employee Stock Option [Member] | Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	529,096
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		108,361
Restricted Stock Units (RSUs) [Member] | Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	94,989